Navigation Links
Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
Date:12/17/2007

losuppression, cardiotoxicity and peripheral neuropathy.

Accrual is continuing in this Phase 2 trial. Up to 20 additional patients are anticipated to be treated with the Injectable Suspension formulation of tanespimycin.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematologic and solid tumors and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division through a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors.

Kosan's motilin agonist, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GERD).

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements regarding the further development and potential
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
2. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
3. 3 strikes, youre out? Refiling of Amendment to Change Constitution to Criminalize Stem Cell Cures Shows Trouble with Anti-Cures Cause
4. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
5. International Survey Shows People Over Forty Ignore Risk of Blindness
6. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
7. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
8. Video shows buckyballs form by shrink wrapping
9. National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, Inc., the ... their 2nd generation cell therapy POD® design. The 2nd generation portfolio not only ... a new POD® design. , “G-CON first offered our miniPOD CT product ...
(Date:7/29/2015)... ... July 29, 2015 , ... Brady (NYSE:BRC), a global leader ... . To align chemical container labeling with OSHA’s updated Hazard Communication (HazCom) Standard ... an example of an accurate label, and pictogram uses and meanings. , “With ...
(Date:7/29/2015)... , July 29, 2015  Therapath Neuropathology ... announces increased partnerships with VA and Military Medical ... Nerve Fiber Density (ENFD) and Sweat Gland Nerve ... fiber neuropathy ( https://therapath.com/skin ). ... Fiber Density (ENFD) on punch skin biopsy is ...
(Date:7/29/2015)... England , July 29, 2015  Indivior PLC ... (NDA) for naloxone nasal spray was accepted and received ... (FDA) for the treatment of opioid overdose. This naloxone ... naloxone specially formulated for optimal absorption into the nasal ... require minimal training so individuals may be better equipped ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Brady Announces a New GHS Label Guide 2Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
... ... expansion, FORT WORTH, Texas, June 9 ... of,Michael J. "Mike" Tansey as Chief Executive Officer., "I am delighted ... a period of accelerated growth," said Mr. Tansey. "The acquisition of,RegionalHelpWanted.com earlier ...
... Capital Markets ... -,- New Role Emphasizes Strategic Growth Plan and Capital Markets Interaction ... ... or "the Company"), a pharmaceutical,company dedicated to improving health through the development, manufacture,and commercialization of ...
... Hearing -, MONTVALE, N.J., June 9 Memory ... June 6, 2008 it received a,letter from the NASDAQ ... not regained compliance with the $1.00 bid,price requirement set ... delisting from The NASDAQ Global Market, unless the Company,requests ...
Cached Biology Technology:onTargetjobs Announces Appointment of Michael Tansey as New CEO 2American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer 2American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer 3Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter 2Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter 3
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015  Synaptics ... interface solutions, announced today that it will report financial ... on Thursday, July 30, 2015 after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/7/2015)... Research and Markets ... the "Capacitive Fingerprint Sensors Patent Landscape" ... date, fingerprint sensing technology is the most reliable ... well developed. This patent landscape focuses on fingerprint ... domain of capacitive fingerprint sensors is closely linked ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... disease ever eradicated. In two studies in the Dec. 15 ... scientists are working to ensure that once it is gone, ... immune systems were weakened by HIV would re-introduce poliovirus into ... switching forms of vaccine from a live, attenuated vaccine to ...
... article on PLoS Biology, with pictures! , When chimpanzees ... known about great ape behavior in the wild. The sighting was ... of Mammalogy (recounted by primatologist Frans de Waal in The Ape ... saw a chimp “come ambling round a bend bearing an armful ...
... that data from its program to develop a ... 45th Annual Interscience Conference on Antimicrobial Agents and ... represents the first demonstration that cells can be ... Sangamo's proprietary zinc finger DNA-binding protein nucleases (ZFNTM) ...
Cached Biology News:Polio vaccination strategies assessed as eradication nears 2Polio vaccination strategies assessed as eradication nears 3Wild Gorillas Handy with a Stick 2Wild Gorillas Handy with a Stick 3Sangamo BioSciences demonstrates its ZFP treatment protects cells from HIV infection 2
The Wellwash 4 Mk 2 microplate washer combines flexibility, simplicity and ease of use. This reliable microplate washer meets the exacting standards of today's ELISA assay requirements....
... Interacting Protein/PBIP1 (phospho T78) ( Abpromise ... Antigen: Synthetic peptide: ... of Human MLF1 Interacting Protein ... 359815 Swiss Protein ...
... genetically engineered endonuclease. This unique enzyme degrades ... having no proteolytic activity. It is effective ... possesses an exceptionally high specific activity. Ideal ... proteins, its use enables compliance with FDA ...
... handy dispensers save space and organize ... other garb. They are the perfect ... used in labs, processing and manufacturing. ... and the particles they attract. Many ...
Biology Products: